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were calculated for each treatment strategy and severity level. Four types of items 
were surveyed: treatment strategy for VCF (A.hospitalization only, B.hospitalization 
to outpatient, C.outpatient visit only, D.operation, E.follow-up only, F.other), treat-
ment period of each VCF therapy (length of stay and outpatient visit), examination
items (diagnostic imaging, laboratory test) and therapeutic regimens (use of cast or 
hard/soft corset, rehabilitation, nerve block, medication). Severity of VCF was classi-
ﬁ ed into three levels: status1(lumbar back pain;/ADL impairment;-/neurological 
symptoms;-), status2(//), status3(//). RESULTS: The questionnaire was 
addressed to 83 institutions, and responses from 68 (response rate 82%) were received. 
Of these, 65 responses were available for estimation. When considering the propor-
tions of treatment strategies (A to C), the expected medical costs for each status were: 
status1; US$1637, status2; US$4485 and status3; US$7962 (1US$  92JPY). The 
expected medical cost of CMM for a patient with osteoporotic VCF in Japan was 
estimated at US$4,032, and the total annual costs of CMM for VCF on a national 
scale were estimated to be US$1.18 billion. CONCLUSIONS: Japan being an aging 
society, the burden of illness for VCF is a signiﬁ cant issue. Further standardization
and customization of treatment modalities are expected for optimal allocation of 
medical resources.
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OBJECTIVES: Rituximab (RTX) and abatacept (ABAT) are novel therapies to treat 
moderate to severe Rheumatoid Arthritis (RA). This analysis was conducted to evalu-
ate the cost-effectiveness of these two therapies in patients with active RA who have
had an inadequate response to anti-tumour necrosis factor (TNF) inhibitor therapies 
from the Ontario Ministry of Health perspective. METHODS: A cost-utility model
was used to evaluate the direct costs and outcomes of a standard Canadian treatment
sequence in the absence and presence of either RTX  methotrexate (MTX) or ABAT
 MTX after failure of one anti-TNF. The model simulated 10,000 RA patients over 
a life time. RTX and ABAT were evaluated against the following standard Canadian
treatment sequence after failure of one anti-TNF (etanercept): adalimumab  MTX, 
inﬂ iximab  MTX, leﬂ unomide, gold, cyclosporine and palliative care. Baseline char-
acteristics from REFLEX (Randomized Evaluation of Long-term Efﬁ cacy of Rituximab 
in RA) clinical trial were: mean age, 52.2 years; mean HAQ score, 1.88. ACR response 
rates from RCTs were placebo-adjusted to minimize bias from cross-trial comparisons. 
All relevant direct costs were included in the model including drug costs, administra-
tion and monitoring, and adverse events. Observational data were used to estimate
long-term HAQ progression and average time on treatment for patients responding
to therapy. Costs and beneﬁ ts were discounted at 5% per annum. RESULTS: The 
introduction of RTX following failure of one biologic resulted in a gain of 0.443 
QALYs at an additional total cost of $3710 resulting in an ICER of $8380/QALY. 
The introduction of ABAT following failure of one biologic resulted in a gain of 0.387
QALYs at an additional total cost of $18,588 resulting in an ICER of $48,000/QALY.
CONCLUSIONS: Rituximab is economically attractive from a Canadian payer per-
spective and is a cost effective treatment option over abatacept when compared in the
studied population.
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OBJECTIVES: To assess the extension in which the participation of a patient in a
support program contributes with increased osteoporosis treatment compliance. Trials 
demonstrated that the compliance rates to oral bisphosphonates therapy present a 
signiﬁ cant drop along the ﬁ rst year of treatment and continue declining year after year.
The objective of a support program is to provide patient’s support providing informa-
tion about the disease, to interchange experiences with other patients, provide high 
calcium content nutrition tips and proper physical activities. METHODS: Quantita-
tive study conducted through personal and individual interviews using a structured
questionnaire. Two hundred and twenty interviews were conducted with female 
patients that concluded the bisphosphonate treatment, divided in two groups: one 
hundred-two registered and one hundred and eighteen non-registered into a support
program. RESULTS: The average treatment period with bisphosphonate between the
patients registered in the program is of 11 months vs. 4 months for non-registered
patients. The main causes of impact on the continuous use of bisphosphonate of the
patients non-registered in a support program include the treatment side effects (28% 
vs. 11%; p  0.002). From the total of patients interrupting the intake of bisphospho-
nate due to side effects the largest number are due to gastric problems. However, the
patients registered in a support program reach the treatment ﬁ nal (34% vs. 15%; 
p  0.01). CONCLUSIONS: The patients registered in a support program present the
tendency to follow the prescription and remain for a longer time period in the therapy. 
It is perceived that when the patients has access to wider information about the disease, 
which is one of the main objectives of a treatment support program, the therapy dis-
continuation rate due to side effects is lower. Because the patients are aware about 
the occurrence of gastric issues, they properly follow the guidelines, avoiding them
and reaching the treatment ﬁ nal.
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OBJECTIVES: The Brace Questionnaire (BrQ) is a recently-developed, condition-
speciﬁ c tool used to measure quality of life (QoL) in subjects treated with spinal 
bracing. While corrective bracing for adolescent idiopathic scoliosis (AIS) has more 
favourable outcomes when patients are compliant, one must appreciate that bracing
itself may be a stressful and traumatic experience, and compliance with a bracing
protocol is likely to be dependent upon patients’ physical, emotional and social well-
being. Using the BrQ we sought to explore relationships between QoL and compliance
with treatment. METHODS: The BrQ was administered to 31 AIS patients after 
a minimum of 1 year of wearing a brace for 1 year. Subjects were 13–16 year-old 
girls with signiﬁ cant deformity (Cobb angles 25–40 degrees). Participants were
divided into two groups according to their level of compliance with the bracing 
protocol. BrQ sub- and total scores were compared between the two groups using the 
t-test for comparison of means. RESULTS: Twenty participants were classiﬁ ed as 
compliant and 11 as non-compliant. Mean total BrQ scores (expressed as %) were 
83.7 for the compliant group and 64.4 for the non-compliant group (p  0.001). The 
compliant group scored signiﬁ cantly higher in six of the eight domains that make 
up the BrQ. Compliant patients had greater vitality and self esteem, and functioned
better in those domains covering physical, emotional and social performance. 
CONCLUSIONS: Poor QoL adversely affects compliance in AIS patients requiring
a brace. Non-compliant patients lack vitality and self esteem, and function poorly 
in the physical, emotional and social domains. Quality of life for adolescents with
idiopathic scoliosis may relate more to psychosocial coping mechanisms than to physi-
cal deformity and its consequences. It is important for remedial programmes to con-
sider personal, peer and family issues as part of improving QoL, promoting compliance 
and correcting deformity.
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OBJECTIVES: Performance-based instruments commonly used in clinical settings 
often do not capture important aspects of the patient’s health experience. Therefore, 
the primary aim of this study was to use a patient-reported outcomes (PRO) question-
naire to investigate patient’s success criteria and expectations when receiving rehabili-
tation services related to falls. METHODS: A group of patients (N  50, age  55) 
receiving physical therapy services were enrolled. Inclusion criteria consisted of: com-
munity dwellers with a history of falling, ability to walk 20 ft, and Mini-Mental State
Exam score 24. The Patient’s Perspective Outcome Questionnaire (PPOQ) was
administered at the initial physical therapy evaluation. PPOQ assesses current levels,
success criteria and expected levels for a number of health domains including: mobility,
self-care, interactions with people, community/social life, energy/drive, mental func-
tion, emotional distress, sensory function, and pain. A 100-point scale is used to assess
levels of interference across domains (0  not affected and 100  most affected).
RESULTS: Participants reported highest scores in the energy/drive (53), mobility (47),
and pain (44) domains. Interactions with people (21) and community/social life (31) 
received the lowest scores, suggesting that domains with a strong social component
were not as affected as domains with a strong physical component. Participants 
required signiﬁ cant improvement to consider their treatment successful. The mobility 
and energy/drive domains required signiﬁ cantly larger reductions than the community/
social life, and interactions with people domains (P  0.006). Across all domains, 
participant’s expectation was that the treatment would not meet their success criteria,
indicating that residual levels of impairment were expected after treatment. CONCLU-
SIONS: The results of this study point out that a number of health domains are sig-
niﬁ cantly affected in this population. These patients have treatment expectations that
exceed the mobility problems for which they were treated. In exploring meaningful 
change, the patient’s expectations and success criteria must be considered.
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OBJECTIVES: To assess symptoms, functionality, quality of life (QoL), and work/ 
productivity loss in Rheumatoid Arthritis (RA) patients treated with subcutaneous 
(SC) biologics. METHODS: Patient-reported data from the 2007 Rheumatoid Arthri-
tis Patient Study were analyzed. Symptoms were measured by morning stiffness,
fatigue, and pain scores deﬁ ned on a scale from 0 (no symptom) to 10 (severe
